Name: Name:Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate
Brand: Angene
SKU: AG00ECE2
Rating: 90 (10 reviews)

Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate

CAS No.:

625115-52-8

Catalog Number:

AG00ECE2

Molecular Formula:

C19H17FN8O2

Molecular Weight:

408.3891

Pack Size

Purity

Availability

Location

Price(USD)

Quantity

5mg

99%

1 week

United States

$207

- +

10mg

99%

1 week

United States

$290

- +

50mg

99%

1 week

United States

$523

- +

100mg

99%

1 week

United States

$807

- +

200mg

99%

1 week

United States

$1040

- +

Product Description

Catalog Number:

AG00ECE2

Chemical Name:

Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate

CAS Number:

625115-52-8

Molecular Formula:

C19H17FN8O2

Molecular Weight:

408.3891

MDL Number:

MFCD22741546

IUPAC Name:

methyl N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate

InChI:

InChI=1S/C19H17FN8O2/c1-30-19(29)24-14-15(21)25-17(26-16(14)22)13-11-6-4-8-23-18(11)28(27-13)9-10-5-2-3-7-12(10)20/h2-8H,9H2,1H3,(H,24,29)(H4,21,22,25,26)

InChI Key:

FTQHGWIXJSSWOY-UHFFFAOYSA-N

SMILES:

COC(=O)Nc1c(N)nc(nc1N)c1nn(c2c1cccn2)Cc1ccccc1F

UNII:

M2A18LL56O

Properties

Complexity:

589

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

408.146g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

408.397g/mol

Monoisotopic Mass:

408.146g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

147A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

1.4

Literature

Title	Journal
Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure.	European urology 20111101
Are we finally on the right track in treating 'difficult' erectile dysfunction patients?	European urology 20111101

Properties